A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram

Objective:To compare sentinel lymph node (SLN)-positive breast cancer patients who had completion axillary dissection (ALND) with those who did not, with particular attention to clinicopathologic features, nomogram scores, rates of axillary local recurrence (LR), and changes in treatment pattern over time. Background:While conventional treatment of SLN-positive patients is to perform ALND, there may be a low-risk subgroup of SLN-positive patients in whom ALND is not required. A multivariate nomogram that predicts the likelihood of residual axillary disease may assist in identifying this group. Methods:Among 1960 consecutive SLN-positive patients (1997–2004), 1673 (85%) had ALND (“SLN+/ALND”) and 287 (15%) did not (“SLN+/no ALND”). We compare in detail the clinicopathologic features, nomogram scores, and rates of axillary LR between groups. Results:Compared with the SLN+/ALND group, patients with SLN+/no ALND were older, had more favorable tumors, were more likely to have breast conservation, had a lower median predicted risk of residual axillary node metastases (9% vs. 37%, P < 0.001), and had a marginally higher rate of axillary LR (2% vs. 0.4%, P = 0.004) at 23 to 30 months’ follow-up; half of all axillary LR in SLN+/no ALND patients were coincident with other local or distant sites. For patients in whom intraoperative frozen section was either negative or not done, the rate of completion ALND declined from 79% in 1997 to 62% in 2003 to 2004 but varied widely by surgeon, ranging from 37% to 100%. For 10 of 10 evaluable surgeons, the median nomogram scores in the SLN+/no ALND group were ≤10.5. Conclusions:SLN+/no ALND breast cancer patients, a selected group with relatively favorable disease characteristics, had a 9% predicted likelihood of residual axillary disease by nomogram but an observed axillary LR of 2%. A gradual and significant decline over time in the rate of completion ALND is associated with, but not entirely explained by, the institution of a predictive nomogram. It is reasonable to omit ALND for a low-risk subset of SLN-positive patients.

[1]  H. Thaler,et al.  Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women , 2002, Annals of Surgical Oncology.

[2]  Sheryl G. A. Gabram,et al.  Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial , 2006, Annals of Surgical Oncology.

[3]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[4]  Gary H Lyman,et al.  Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinoma , 2006, Cancer.

[5]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Brogi,et al.  The Results of Frozen Section, Touch Preparation, and Cytological Smear Are Comparable for Intraoperative Examination of Sentinel Lymph Nodes: A Study in 133 Breast Cancer Patients , 2005, Annals of Surgical Oncology.

[7]  H. Cody,et al.  The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable With That of Axillary Lymph Node Dissection: A Follow-up Study of 4008 Procedures , 2004, Annals of surgery.

[8]  E. Barrera,et al.  Axillary Recurrence After Sentinel Node Biopsy , 2004, Annals of Surgical Oncology.

[9]  Hiram S. Cody,et al.  A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.

[10]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[11]  J. Kuhn,et al.  Preliminary Outcome Analysis in Patients With Breast Cancer and a Positive Sentinel Lymph Node Who Declined Axillary Dissection , 2003, Annals of Surgical Oncology.

[12]  A. Giuliano,et al.  Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. , 2003, Archives of surgery.

[13]  H. Cody,et al.  Sentinel Lymph Node Biopsy for Breast Cancer: Does Anybody Not Need One? , 2003, Annals of Surgical Oncology.

[14]  R. Mansel,et al.  Sentinel Node Biopsy in Breast Cancer: ALMANAC Trial , 2001, World Journal of Surgery.

[15]  H. Cody,et al.  State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. , 1999, Surgical oncology.

[16]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[17]  B Fisher,et al.  Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. , 1985, The New England journal of medicine.